A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

Inclusion Criteria:

1. Male or female, age ≥18 years at the time of signing informed consent, and at leastthe legal age of consent in countries where it is >18 years.

2. Body mass index (BMI) ≥27 kg/m^2 at screening.

3. Diagnosed with Type 2 diabetes mellitus (T2DM) (defined as Glycosylated haemoglobinA1c (HbA1c) ≥6.5% [≥48 mmol/mol]) at least 180 days prior to screening.

4. HbA1c ≥6.5% (≥48 mmol/mol) and <10% (<86 mmol/mol) as measured by the centrallaboratory at screening.

5. Currently treated for T2DM with either diet and exercise alone or stable treatment (for at least 3 months prior to screening) per treatment guidelines.

6. History of at least one self-reported unsuccessful dietary effort to lose bodyweight Further inclusion criteria apply.

Exclusion Criteria:

1. Body weight change (self-reported) of >5% within 3 months before screening.

2. Treatment with any medication for the indication obesity within 3 months beforescreening.

3. Treatment with any medication for indication of T2DM other than stated in theinclusion criteria and glucagon-like peptide-1 receptor (GLP-1R)-based agonists) anddipeptidyl peptidase 4 inhibitor [DPP-4il).

4. Known clinically significant gastric emptying abnormality (e.g., severe diabeticgastroparesis or gastric outlet obstruction).

5. History of either chronic or acute pancreatitis or elevation of serum lipase oramylase >2x upper limit of normal (ULN)) as measured by the central laboratory atscreening.

6. Personal or family history of medullary thyroid carcinoma (MTC) or multipleendocrine neoplasia syndrome type 2 (MEN 2).

Further exclusion criteria apply.